Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
Status:
NOT_YET_RECRUITING
Trial end date:
2032-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized Phase II study of intermittent versus continuous venetoclax therapy with Acalabrutinib in previously untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)